Pfizer/Neurocrine Indiplon Looking For First Sleep Interruption Claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer and Neurocrine Biosciences are hoping that indiplon will be the first sleep agent to receive approval for treating sleep interruption, with middle of the night dosing. An NDA submission for immediate- and modified-release formulations is planned for early 2004.